(11alpha,13E,15S,19R)-11,15,19-Trihydroxy-9-oxoprost-13-en-1-oic acid(CAS: 64625-55-4)

This compound is subject to various regulatory guidelines, including GHS classification for hazardous substances, REACH regulations for the registration, evaluation, authorization, and restriction of chemicals in the European Union, as well as FDA and EPA requirements for safety and environmental protection in the United States. It is important to ensure compliance with relevant local and international regulations to avoid legal and safety issues.

Alternatives to (11alpha,13E,15S,19R)-11,15,19-Trihydroxy-9-oxoprost-13-en-1-oic acid include similar prostaglandins and their analogs, as well as isomers with different functional groups. Common alternative reagents and synthetic methods should be carefully considered to achieve the desired product profile with higher efficiency and yield.

The market for (11alpha,13E,15S,19R)-11,15,19-Trihydroxy-9-oxoprost-13-en-1-oic acid shows increasing interest in its potential applications in pharmaceuticals, particularly in pain management and inflammation therapy. Research trends are focusing on understanding its biological activity and exploring its synthetic analogs to enhance therapeutic effects and reduce side effects.

Waste containing (11alpha,13E,15S,19R)-11,15,19-Trihydroxy-9-oxoprost-13-en-1-oic acid should be managed according to local hazardous waste regulations. Proper waste collection and disposal methods should be implemented, such as incineration at a licensed facility or professional waste disposal services. Environmental protection precautions, including proper containment and handling to prevent accidental releases, are essential to ensure safety and compliance with environmental standards.